论文部分内容阅读
银河证券首席总裁顾问左小蕾认为,新股发行由核准制向注册制过渡后,打新股就更需要投资者的理性判断。随着IPO重新开闸,新股开始海量登陆A股市场。日前,我武生物、新宝股份分别以30倍、39倍的发行市盈率打响了IPO重启后的“头炮”。近500名网下投资者的参与,超百倍的超额认购,都显示了这两只新股网下申购形势的火爆。新宝股份发布定价及网下配售结果公告显示,其最终发行价格定为10.50元/股,对应的市盈率为30.08倍,高于行业平均市盈率。
Zuo Xiaolei, chief consultant of Galaxy Securities, believes that after the issuance of new shares from the approval system to the registration system, playing the new shares even more need investors’ rational judgment. With the IPO restart, new shares began to mass landing A-share market. Recently, I Wu biological, Xinbao shares were 30 times, 39 times the issue price-earnings ratio IPO restart after the “first shot.” Nearly 500 investors under the net participation, over a hundred times over-subscribed, have shown that the two new shares under the net purchase situation hot. Xinbao shares issued pricing and offline placement notice announcement, the final issue price of 10.50 yuan / share, the corresponding price-earnings ratio of 30.08 times, higher than the industry average price-earnings ratio.